

Apple Health Policies

Antihyperlipidemics : PCSK-9 Inhibitors

▶ Recommendation:

- ▶ All products are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Antihyperlipidemics : PCSK-9 Inhibitors

▶ **Motion:** I move that all products in the Antihyperlipidemics – PCSK-9 Inhibitor drug class are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **Motion: Huynh**

▶ **2nd: Buccola**

ADHD / Narcolepsy Agents

- ▶ Stimulants

- ▶ Non-Stimulants

- ▶ **Recommendation:**

- ▶ All products are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

ADHD/Narcolepsy Agents

- ▶ Stimulants
- ▶ Non-Stimulants
- ▶ **Motion:** I move that all products in the ADHD / Narcolepsy drug classes listed on slide #4* are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Storhaug**
- ▶ **2nd: Huynh**

*formerly slide #3 in the transcript

Asthma and COPD Agents – Monoclonal Antibodies

▶ Recommendation:

- ▶ All products are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Approve the prior authorization criteria policies 44.60.30-2 and 44.60.40-2 as reviewed and edited.**

Asthma COPD Agents – Monoclonal Antibodies

▶ **Motion:** I move that all products in the Asthma and COPD Agents – Monoclonal Antibody drug class are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred. We **approve the prior authorization criteria policies 44.60.30-2 and 44.60.40-2** as reviewed and edited.

▶ **Motion: Buccola**

▶ **2nd: Lee**

Dermatologics – Atopic Dermatitis Agents

▶ Recommendation:

- ▶ All products are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ Approve prior authorization criteria as reviewed and edited in policy 90.27.30.20

Dermatologics – Atopic Dermatitis Agents

▶ Recommendation:

- ▶ All products are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Dermatologics – Atopic Dermatitis

- ▶ **Motion:** I move that all products in the Dermatologics – Atopic Dermatitis drug class are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred. We approve prior authorization criteria as reviewed and edited in policy 90.27.30.20, 90.23.00, and 90.78.40.
- ▶ **Motion: Chew**
- ▶ **2nd: Schwilke**
- ▶ **Motion: Huynh**
- ▶ **2nd: Buccola**

Antivirals – HIV Agents

▶ Recommendation:

- ▶ All products are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA in consultation with the Department of Health's HPSG Clinical Advisory Committee.
- ▶ All non-preferred products require a trial of one preferred product with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Antivirals – HIV Agents

- ▶ **Motion:** I move that all products in the Antiviral HIV Agents drug class are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA in consultation with the Department of Health's HPSG Clinical Advisory Committee and current clinical guidelines. All non-preferred products require a trial of one preferred product with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Chew**
- ▶ **2nd: Flatebo**

Drug Class Reviews

Asthma and COPD Agents

- ▶ Anticholinergics
- ▶ Beta Agonists – Short Acting (Inhaled)
- ▶ Beta Agonists – Short Acting (Oral)
- ▶ Beta Agonists – Long Acting
- ▶ Inhaled Corticosteroids
- ▶ Inhaled Corticosteroid Combinations
- ▶ Long Acting Muscarinic Agents
- ▶ Long Acting Muscarinic Agents / LABA Combinations
- ▶ Phosphodiesterase Inhibitors

Asthma and COPD Agents

▶ Recommendation:

- ▶ All products in the drug classes listed on slide 14 are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Asthma COPD Agents –

- ▶ **Motion:** I move that all products in the Asthma and COPD Agents - drug classes listed on slide 14* are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA. Each drug class listed must have at least two preferred agents when possible. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Buccola**
- ▶ **2nd: Lee**

*formerly slide #18 in the transcript

Dermatologics

- ▶ Agents for External Genital and Perianal Warts
- ▶ Antipsoriatic Agents – Oral
- ▶ Antipsoriatic Agents - Topical
- ▶ Emollients
- ▶ Immunomodulating Agents - Topical
- ▶ Keralytic / Antimitotic Agents

Dermatologics

▶ Recommendation:

- ▶ All products in the drug classes listed on slide 17 are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Dermatologics

- ▶ **Motion:** I move that all products in the Dermatologics drug classes listed on slide 17* are considered safe and efficacious and are eligible for preferred status and grandfathering at the discretion of HCA. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flatebo**
- ▶ **2nd: Brown**

*formerly slide #21 in the transcript